44% fewer infants requiring hospitalisation for RSV infection
For decades, respiratory syncytial virus arrived each season as an unavoidable burden on the youngest and most vulnerable, filling paediatric wards with infants struggling to breathe. Australia has now produced the first real-world evidence from the Southern Hemisphere that a layered immunisation strategy — vaccinating pregnant mothers and administering monoclonal antibody therapy to newborns — can meaningfully interrupt that pattern, reducing infant hospitalisations by 44%. It is a reminder that when medicine addresses vulnerability at its earliest point, the returns can be profound.
- RSV has long been a predictable seasonal crisis in paediatric wards, with infants under six months facing the gravest risk of severe respiratory failure.
- Australia's dual-track program — maternal vaccination at 81% effectiveness and nirsevimab immunotherapy at 90% — has produced the steepest real-world reduction in infant RSV hospitalisations yet recorded in the Southern Hemisphere.
- The study, drawn from 1,404 children with documented immunisation status across the PAEDS-FluCAN surveillance network, gives the strategy its first rigorous field validation outside Northern Hemisphere conditions.
- Though published as a preprint awaiting peer review, the data is substantial enough that researchers and clinicians are already treating it as confirmation that the layered approach works as designed.
- The 44% drop translates directly into hundreds of infants per year spared from oxygen support, hospital stays, and the cascade of fear and cost that severe newborn illness brings.
Australia's paediatric wards are admitting far fewer infants with respiratory syncytial virus since two immunisation programs began operating in parallel. The reduction — 44% fewer hospitalisations — is the first real-world measure of what these interventions can achieve in Australian conditions, and the numbers behind it are striking.
Researchers from the University of Western Australia drew on the PAEDS-FluCAN surveillance network, analysing outcomes for 1,404 children with documented immunisation status. Mothers who received RSV vaccination during pregnancy passed protection to their newborns with 81% effectiveness. Infants who received nirsevimab — a monoclonal antibody given in the first weeks of life — showed 90% effectiveness against severe infection requiring hospital care.
The design was deliberate: maternal antibodies provide passive immunity from birth, while nirsevimab extends and reinforces that protection through the months when RSV risk peaks. RSV inflames the small airways, causing wheezing and breathing difficulty that can escalate to oxygen support or mechanical ventilation in the very young. Before these programs, RSV season meant predictable waves of sick babies. The layered strategy was built to interrupt that cycle.
What gives the finding particular weight is its geography. The Southern Hemisphere has different seasonal rhythms, population patterns, and healthcare infrastructure than the settings where most earlier RSV research was conducted. Demonstrating that the combined approach works here validates it for Australia's health system and offers a template for neighbouring countries facing the same burden.
The research remains a preprint, not yet formally peer-reviewed. But with over 1,400 children tracked against clear immunisation records, the dataset is substantial. A 44% reduction means hundreds of infants each year who avoid severe illness, whose parents avoid the ordeal of a critically unwell newborn, and whose care does not consume hospital resources that could be needed elsewhere. For a virus that circulated for decades without effective prevention, it marks a genuine turning point.
Australia's hospitals are admitting far fewer newborns with respiratory syncytial virus than they were before two new immunisation programs took hold. The drop is steep: 44% fewer infants requiring hospitalisation for RSV infection since maternal vaccination and infant immunotherapy rolled out. This is the first real-world evidence from Australia showing what the programs can actually do.
The data comes from the PAEDS-FluCAN Network, a surveillance system that tracked outcomes across the country. Researchers from the University of Western Australia analysed 1,404 children whose immunisation status was documented and measured how well each approach worked. The numbers were striking. Mothers who received RSV vaccination during pregnancy passed protection to their babies with 81% effectiveness. Newborns who received nirsevimab—an immunotherapy administered in the first weeks of life—showed 90% effectiveness against severe RSV infection requiring hospital care.
RSV is a virus that hits hardest in the very young. It causes inflammation in the small airways of the lungs, leading to wheezing, difficulty breathing, and in severe cases, the need for oxygen support or mechanical ventilation. Infants under six months are at highest risk of serious disease. Before these programs existed, RSV season meant predictable waves of sick babies in paediatric wards. The virus spreads easily through respiratory droplets, and once it takes hold in a household or childcare setting, it moves quickly through the vulnerable population.
The hybrid approach—vaccinating pregnant women and then giving newborns a separate immunotherapy—was designed to layer protection. Maternal antibodies provide immediate, passive immunity from birth. The nirsevimab, a monoclonal antibody, extends and reinforces that protection through the critical first months when RSV risk is highest. Neither approach alone was expected to be perfect. Together, they appear to be remarkably effective.
What makes this finding significant is not just the number but the context. This is the first study measuring how well such a combined RSV immunisation program actually works in real Australian conditions. The Southern Hemisphere has different seasonal patterns than the Northern Hemisphere, different population densities, different healthcare infrastructure. Showing that the strategy works here, with these numbers, validates the approach for Australia's own health system and potentially for other countries in the region facing the same burden.
The research was published as a preprint, meaning it has been shared with the scientific community but not yet undergone formal peer review. Still, the data is substantial—over 1,400 children with clear records of what they received and what happened to them. Hospitals tracked who came through their doors with RSV, and researchers matched that against immunisation records to calculate how much protection each intervention provided.
A 44% reduction in hospitalisations translates to hundreds of infants per year who avoid severe respiratory illness, who do not need to spend nights in hospital, who do not require supplemental oxygen or intensive monitoring. Their parents avoid the fear and disruption of having a critically ill newborn. The healthcare system avoids the cost and resource strain of managing those cases. For a virus that has circulated in human populations for decades with no effective prevention, this represents a meaningful shift in what medicine can now offer.
Citas Notables
This is the first study estimating immunisation effectiveness of a hybrid program in Australia and the Southern Hemisphere, demonstrating that the hybrid respiratory syncytial virus immunisation program is highly effective against RSV-associated hospitalisation in children.— University of Western Australia research team
La Conversación del Hearth Otra perspectiva de la historia
Why does RSV hit newborns so hard compared to older children?
The lungs of a newborn are still developing, and their immune system hasn't encountered RSV before. When the virus infects those tiny airways, the inflammation can narrow them dangerously. An older child's immune system recognises the threat faster and mounts a response before things get critical.
So the maternal vaccination—that's the mother getting vaccinated while pregnant?
Yes. She develops antibodies against RSV, and those antibodies cross the placenta and enter the baby's bloodstream. The baby is born already protected, at least partially. It's passive immunity, borrowed from the mother, but it's there from day one.
And then nirsevimab is given separately to the baby?
Right. It's a monoclonal antibody—a lab-made protein that targets RSV specifically. The baby gets it injected in the first weeks of life. It's not a vaccine in the traditional sense; it's direct protection, like giving the baby extra antibodies to fight the virus if exposure happens.
Why not just do one or the other?
Because neither is perfect alone. Maternal antibodies fade over time as the baby's own immune system takes over. Nirsevimab extends the window of protection through the most dangerous months. Together they cover the gap better than either could alone.
The 44% reduction—does that mean some babies still get RSV even with both?
Yes. The programs don't prevent all cases, but they prevent the severe ones that land babies in hospital. Some infants might still get infected but fight it off at home with mild symptoms. That's actually a success—it's the hospitalisation we're trying to prevent.
What happens to babies born to mothers who didn't get vaccinated?
They only have access to nirsevimab if they receive it. Without maternal antibodies and without the immunotherapy, they're vulnerable during those first critical months. That's why the dual approach matters—it catches more infants, protects them more completely.